Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

406 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Elderly and aged asthma have different characteristics: results of a multicenter study.
Damadoğlu E, Aktaş ÖÖ, Gemicioğlu B, Yilmaz N, Bozkuş F, Ayhan V, Kalpaklioğlu AF, Erkekol FÖ, Havlucu Y, Erel F, Aydin Ö, Ekici A, Baççioğlu A, Bariş SA, Buhari GK, Ceyhan B, Göksel Ö, Köse M, Dursun AB, Yildiz F, Yorgancioğlu A, Işik SR, Ediger D, Oğuzülgen İK, Demir AU, Karakaya G, Kalyoncu AF. Damadoğlu E, et al. Among authors: aktas oo. Turk J Med Sci. 2023 Nov 18;54(1):309-315. doi: 10.55730/1300-0144.5792. eCollection 2024. Turk J Med Sci. 2023. PMID: 38812643 Free PMC article.
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Cree BAC, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, She D, Rees W, Smith M, Cimbora D, Katz E, Bennett JL; N-MOmentum study investigators. Cree BAC, et al. Among authors: aktas o. Lancet Neurol. 2024 Jun;23(6):588-602. doi: 10.1016/S1474-4422(24)00077-2. Lancet Neurol. 2024. PMID: 38760098 Clinical Trial.
Improving the sensitivity of myelin oligodendrocyte glycoprotein-antibody testing: exclusive or predominant MOG-IgG3 seropositivity-a potential diagnostic pitfall in patients with MOG-EM/MOGAD.
Jarius S, Ringelstein M, Schanda K, Ruprecht K, Korporal-Kuhnke M, Viehöver A, Hümmert MW, Schindler P, Endmayr V, Gastaldi M, Trebst C, Franciotta D, Aktas O, Höftberger R, Haas J, Komorowski L, Paul F, Reindl M, Wildemann B. Jarius S, et al. Among authors: aktas o. J Neurol. 2024 Apr 13. doi: 10.1007/s00415-024-12285-5. Online ahead of print. J Neurol. 2024. PMID: 38609667
Correction to: Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
Kümpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, Häußler V, Havla J, Hellwig K, Hümmert MW, Jarius S, Kleiter I, Klotz L, Krumbholz M, Paul F, Ringelstein M, Ruprecht K, Senel M, Stellmann JP, Bergh FT, Trebst C, Tumani H, Warnke C, Wildemann B, Berthele A; Neuromyelitis Optica Study Group (NEMOS). Kümpfel T, et al. Among authors: aktas o. J Neurol. 2024 Jun;271(6):3702-3707. doi: 10.1007/s00415-024-12288-2. J Neurol. 2024. PMID: 38578500 Free PMC article. No abstract available.
Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are associated with distinct disease trajectories.
Gross CC, Schulte-Mecklenbeck A, Steinberg OV, Wirth T, Lauks S, Bittner S, Schindler P, Baranzini SE, Groppa S, Bellmann-Strobl J, Bünger N, Chien C, Dawin E, Eveslage M, Fleischer V, Gonzalez-Escamilla G, Gisevius B, Haas J, Kerschensteiner M, Kirstein L, Korsukewitz C, Lohmann L, Lünemann JD, Luessi F, Meyer Zu Hörste G, Motte J, Ruck T, Ruprecht K, Schwab N, Steffen F, Meuth SG, Paul F, Wildemann B, Kümpfel T, Gold R, Hahn T, Zipp F, Klotz L, Wiendl H; German Competence Network Multiple Sclerosis (KKNMS). Gross CC, et al. Sci Transl Med. 2024 Mar 27;16(740):eade8560. doi: 10.1126/scitranslmed.ade8560. Epub 2024 Mar 27. Sci Transl Med. 2024. PMID: 38536936
Antibacterial properties of marine algae incorporated polylactide acid membranes as an alternative to clinically applied different collagen membranes.
Weitkamp JT, El Hajjami S, Acil Y, Spille J, Sayin S, Okudan ES, Saygili EI, Veziroglu S, Flörke C, Behrendt P, Wiltfang J, Aktas OC, Gülses A. Weitkamp JT, et al. Among authors: aktas oc. J Mater Sci Mater Med. 2024 Jan 29;35(1):9. doi: 10.1007/s10856-024-06778-y. J Mater Sci Mater Med. 2024. PMID: 38285196 Free PMC article.
Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD.
Duchow A, Bellmann-Strobl J, Friede T, Aktas O, Angstwurm K, Ayzenberg I, Berthele A, Dawin E, Engels D, Fischer K, Flaskamp M, Giglhuber K, Grothe M, Havla J, Hümmert MW, Jarius S, Kaste M, Kern P, Kleiter I, Klotz L, Korporal-Kuhnke M, Kraemer M, Krumbholz M, Kümpfel T, Lohmann L, Ringelstein M, Rommer P, Schindler P, Schubert C, Schwake C, Senel M, Then Bergh F, Tkachenko D, Tumani H, Trebst C, Vardakas I, Walter A, Warnke C, Weber MS, Wickel J, Wildemann B, Winkelmann A, Paul F, Stellmann JP, Häußler V; Neuromyelitis Optica Study Group (NEMOS). Duchow A, et al. Among authors: aktas o. Ann Neurol. 2024 Apr;95(4):720-732. doi: 10.1002/ana.26858. Epub 2024 Jan 13. Ann Neurol. 2024. PMID: 38086777
406 results